What kind of biotech company returns billions to its investors without ever opening a lab, commercializing a drug, or going public with an IPO?
Nimbus Therapeutics. After raising $125 million just a year ago and selling a still-experimental pill to Takeda Pharmaceutical in a deal earlier this year that could be worth as much as$6 billion, the small Boston-based biotech is back for more.
View the article
